Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-β Inhibitor and PD-1 Inhibitor Cemiplimab
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Cemiplimab (Primary) ; SAR 439459 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms TACTIC TRIAL
- 08 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 03 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 25 Feb 2021 Status changed from not yet recruiting to recruiting.